Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA.
Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA.
Curr Oncol. 2022 Oct 9;29(10):7552-7557. doi: 10.3390/curroncol29100594.
Mantle cell lymphoma (MCL) is an uncommon subcategory of non-Hodgkin lymphoma (NHL). Pathogenesis primarily includes overexpression of and along with other molecular aberrations. Lutetium Lu-DOTATATE is a radiolabeled somatostatin analogue used for the treatment of gastrointestinal neuroendocrine tumors. There are no clinical data supporting the use of Lutetium Lu-DOTATATE in the treatment of lymphoma. We describe the case of an 84-year-old man with a history of MCL and carcinoid tumor of the lung. Following progression of the carcinoid malignancy, the patient was treated with Lutetium Lu-DOTATATE. After treatment, there was an overall improvement of the patient's MCL that was demonstrated by stable lymphadenopathy on serial CT scans and down-trend of the absolute lymphocyte count. Therefore, we hypothesize that Lu-DOTATATE might have a role and can be repurposed for treating MCL.
套细胞淋巴瘤（MCL）是非霍奇金淋巴瘤（NHL）的一种罕见亚型。发病机制主要包括 和 过度表达以及其他分子异常。镥 Lu-DOTATATE 是一种放射性标记的生长抑素类似物，用于治疗胃肠道神经内分泌肿瘤。目前尚无临床数据支持将 Lu-DOTATATE 用于治疗淋巴瘤。我们描述了一例 84 岁男性，患有 MCL 和肺类癌肿瘤。类癌恶性肿瘤进展后，该患者接受了 Lu-DOTATATE 治疗。治疗后，患者的 MCL 总体得到改善，连续 CT 扫描显示淋巴结肿大稳定，绝对淋巴细胞计数呈下降趋势。因此，我们假设 Lu-DOTATATE 可能具有一定作用，并可重新用于治疗 MCL。
